Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia
### Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia
Leukemia
#ALL #CAR-Ttherapy #Leukemia #CancerResearch #B_ALL #LeukemiaTreatment
Recently, a Chinese medical team published a notable study titled “Five-year outcome of CD19 combined with CD22 CAR-T cell therapy in B-ALL patients relapsed after allo-transplantation.” The research highlights the long-term efficacy of combined CD19 and CD22 CAR-T cell therapy in patients with relapsed acute B-lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HCT). This breakthrough has not only brought new hope to B-ALL patients but also attracted significant global attention.
**Background and Significance**
Acute B-lymphoblastic leukemia is a hematologic malignancy with poor prognosis, especially for patients who experience relapse after allo-HCT, where survival rates are significantly reduced. CAR-T cell therapy in China has shown increasingly positive results in treating B-ALL, particularly in targeting the CD19 antigen. However, the effects of targeting the CD22 antigen and its potential in combination with CD19 therapy are still under deeper investigation.
**Study Design and Methodology**
Based on a previous phase I clinical trial, this study involved a follow-up of 27 patients who had received CD19 CAR-T treatment. To comprehensively assess the treatment’s efficacy, the study also included three additional patients who experienced relapse with minimal residual disease (MRD) in the bone marrow. Although these patients did not meet the initial trial’s criteria, they received combined CD19 and CD22 CAR-T cell therapy under the same protocol. The CAR-T cells used in this study were second-generation designs created via lentiviral vector transfection.
**Study Results**
After a 5-year follow-up, the Chinese research team found that combined CD19 and CD22 therapy significantly improved patients’ long-term survival rates. Among the 30 patients who completed the combined therapy, the median follow-up time was 64.4 months. After two complete treatment cycles, patients maintained sustained remission. Survival analysis showed that the 3-year and 5-year overall survival rates reached 79% and 75%, respectively, with event-free survival rates of 54% and 50%. These results indicate that combined CD19 and CD22 CAR-T cell therapy offers substantial long-term efficacy for relapsed B-ALL patients.
**Conclusions and Future Outlook**
This study not only validates the potential of CAR-T cell therapy in hematologic malignancies but also provides new therapeutic insights for clinical practice. The combination of CD19 and CD22 holds promise for offering a more effective treatment option for B-ALL patients who relapse after allo-HCT, significantly improving their long-term survival rates.
As research in CAR-T cell therapy deepens, we may see more targeted approaches and optimized treatment protocols emerge. China’s active exploration and innovation in this field bring renewed hope to hematologic cancer patients worldwide, with the expectation that CAR-T therapy will further improve survival rates and quality of life for B-ALL patients in the near future.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#Immunotherapy #CD19CD22Combo #StemCellTransplant #ChinaMedicalResearch #Hematology #CancerBreakthrough #LongTermSurvival #BloodCancer
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s CAR-T Technology Leads the World: A Miraculous Recovery Journey for Children with systemic lupus erythematosus (SLE)
**China’s CAR-T Technology Leads the World: A Miraculous Recovery Journey for Children with systemic lupus erythematosus (SLE)**
LUPUS
#SLE #lupus #systemiclupuserythematosus #CAR_Ttherapy #CancerSurvivor #ChineseHealthcare#PatientStory
In the field of medicine, the boundary between science and miracles is often blurred. This October, news from Zhejiang, China, shocked the world: 20 children suffering from refractory systemic lupus erythematosus (SLE) successfully discontinued the use of steroids and all immunosuppressants after receiving CAR-T cell therapy.
This global breakthrough not only brings hope to patients and their families but also demonstrates the immense potential of CAR-T therapy in the treatment of autoimmune diseases.
### Immune System Reset, New Life Begins
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that many patients struggle to control despite long-term reliance on medications. This clinical trial, led by a team of renowned Chinese medical experts, marks the first time autologous CD19-targeted CAR-T cells have been applied to treat pediatric SLE patients. In just seven months, the symptoms of all 20 children improved significantly, and their quality of life greatly increased.
These children ranged in age from 6 to 19 years, with disease durations varying from four months to 11 years. Prior to receiving CAR-T treatment, they had been on an average of more than five different medications, with some taking as many as nine, yet the results were less than ideal. The introduction of CAR-T therapy became their last hope.
Although CAR-T therapy has already seen widespread application in the field of hematologic malignancies, this treatment for pediatric SLE represents a new frontier for CAR-T technology in autoimmune disease treatment, paving the way for innovative medical exploration.
### Clinical Data: Miracles in Reality
Among the 20 children, many showed remarkable recovery. For example, a 12-year-old girl from Shanghai, who had experienced recurrent lupus flare-ups, with a “butterfly rash” covering her face and massive proteinuria, saw a dramatic improvement after receiving CAR-T therapy. Within six months, she stopped all medications, her proteinuria decreased significantly, and her facial rash completely disappeared. By September, she had returned to school and was living almost normally.
Another 15-year-old girl from Shandong, despite having been diagnosed only two years prior, had progressed rapidly to kidney failure, requiring dialysis. After treatment, her blood creatinine level dropped from 700 μmol/L to 170 μmol/L, and her urine output increased from 50ml to 1000ml, allowing her to fully stop dialysis.
Moreover, all 20 children successfully discontinued steroids and immunosuppressants, and some patients’ disease activity scores dropped to zero. This means their immune systems have been reset, providing long-term control and, in some cases, a complete cure.
### Safety and Side Effects of CAR-T Therapy
Every revolutionary treatment carries risks, but the safety of China’s CAR-T therapy in this trial has been encouraging. CAR-T therapy works by genetically modifying T cells to recognize and attack specific target cells. Some patients experienced mild side effects, such as fever, nausea, and fatigue. Among the 20 children, only three exhibited mild neurological symptoms, which quickly improved with symptomatic treatment.
Research shows that CAR-T treatment in pediatric SLE patients comes with relatively mild side effects, and most patients did not experience any severe adverse reactions. This makes the future of CAR-T therapy in treating refractory lupus even more promising. This technology not only delivers significant therapeutic effects but also restores hope for a better future for these children.
### A Forward-Looking Treatment: From SLE to Other Diseases
Following the success of these 20 SLE cases, the research team plans to extend the application of China’s CAR-T technology to other autoimmune diseases, such as ANCA-associated vasculitis (AAV) and multidrug-resistant steroid-resistant nephrotic syndrome (MDR-SRNS). This means that in the future, more patients will have the opportunity to benefit from this revolutionary therapy.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #Immunotherapy #MedicalBreakthrough #AdvancedMedicine #HealthRecovery
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia(ALL) with a 100% Response Rate!
Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia with a 100% Response Rate!
ALL
In recent years, CAR-T cell therapies from China have garnered global attention in the fight against cancer, and now another CAR-T product is about to hit the market. Priscabtagene Autoleucel Injection (pCAR-19B), developed by China’s Precision Biotech, is specifically designed for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and is currently under priority review for approval. It is poised to become China’s first CAR-T therapy specifically tailored for children and adolescents with acute leukemia.
This groundbreaking therapy has shown remarkable efficacy, achieving a 100% overall response rate in early clinical trials. For patients who no longer respond to conventional treatments, Priscabtagene Autoleucel offers a new lifeline. The therapy has demonstrated superior safety and efficacy in clinical settings, thanks to gene optimization and advanced vector systems that reduce side effects while enhancing effectiveness.
Currently, pCAR-19B has entered Phase II clinical trials, expanding its scope beyond children to include adult patients with relapsed leukemia. It is also being researched for the treatment of other malignant lymphomas, such as diffuse large B-cell lymphoma and follicular lymphoma. This signifies the vast potential of CAR-T therapies in China, promising more effective treatment options for blood cancer patients both domestically and globally.
Precision Biotech’s CAR-T therapy is expected to gain approval soon, contributing to global medical innovation while bringing new hope to countless patients.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
At which stage of treatment is the best time to choose CAR-T therapy?
At which stage of treatment is the best time to choose CAR-T therapy?
CAR-T therapy is often used as a last resort, but it should be introduced earlier for better outcomes. Early use, even as a frontline or 1.5-line treatment, could dramatically increase patient cure rates.
Tumor cells are highly adaptable and intelligent, learning to evade treatments over time. Treating tumors early, before they become stronger, is crucial.
CAR-T should not be considered a “last resort” in treatment, as waiting too long may reduce its effectiveness. It’s better to “kill the tumor when it’s young” before it becomes more resilient and difficult to eliminate.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!
Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!
**Patient Story – Oleg’s Cancer Journey:**
Today, we share the story of a 46-year-old patient from Russia named Oleg. Oleg was diagnosed with follicular lymphoma and, after multiple rounds of chemotherapy, achieved complete remission. Unfortunately, the disease relapsed, with several enlarged lymph nodes appearing in his abdomen and other areas. Faced with this resurgence, Oleg was determined not to give up and decided to seek new treatment options to improve his quality of life.
**Tailor-Made CAR-T Treatment Plan:**
After extensive research, Oleg contacted us and connected with lymphoma experts from our Advanced Medicine in China team. Through video consultations and detailed discussions, he decided to pursue CAR-T cell therapy. With confidence in the potential of Chinese CAR-T therapy, Oleg and his family traveled thousands of miles to China to begin his CAR-T treatment journey.
Given Oleg’s high tumor burden and relapse after chemotherapy, the Chinese medical team customized a bridging therapy for him, combining targeted drugs with low-dose radiotherapy to reduce the tumor burden and improve the immune environment. Special care was taken when designing the radiotherapy plan, as Oleg still had fertility concerns. The team created a personalized treatment plan that balanced safety and effectiveness. During the treatment process, Oleg experienced almost no significant side effects, demonstrating excellent treatment compliance and tolerance. He maintained a strong relationship of trust and communication with the medical team.
**Complete CR – A New Life After Treatment**
Oleg’s CAR-T cell infusion process went smoothly. Despite a history of migraines, he only experienced mild headaches and low-grade fever after the treatment. Under the meticulous care of the treatment team, the CAR-T cells demonstrated strong anti-tumor effects, with minimal side effects. For a patient with a high tumor burden, he only developed grade 1 cytokine release syndrome (CRS), and his blood counts began to recover about a week after the infusion. Overall, he remained in good condition.
Fifteen days after the CAR-T infusion, an abdominal ultrasound showed significant shrinkage of the enlarged lymph nodes. Three months later, a PET-CT scan brought even more surprising news—Oleg’s tumors had completely disappeared, and his response was evaluated as a complete remission (CR). This meant that Oleg had beaten cancer!
Today, Oleg is doing better and better, running daily. He is especially grateful for the support and care provided by the Advanced Medicine in China team and the Chinese experts. Despite being far from home, he never felt inconvenienced during his treatment in China. The doctors and nurses not only communicated with him patiently but also provided significant help in his daily life.
**Why Choose CAR-T Treatment in China?**
CAR-T therapy has shown remarkable efficacy in treating relapsed and refractory follicular lymphoma, with clinical data showing an objective response rate (ORR) of over 90% and a median duration of response exceeding three years! Oleg’s case is a testament to China’s advanced medical technology. Traditional chemotherapy tends to lose effectiveness after repeated treatments, while CAR-T therapy offers the possibility of curing diseases like follicular lymphoma, which were previously considered incurable.
For patients like Oleg, who seek a high-quality life, China’s CAR-T therapy is bringing new hope. 
**World-Class – China’s CAR-T Indications and Beyond**
Today, China’s CAR-T is not only actively involved in global research but is also leading many developments in the CAR-T field. For patients like Oleg with follicular lymphoma, only China and the U.S. have approved CAR-T products targeting this condition. However, China’s CR rate is notably higher.
Currently, China offers the most extensive range of CAR-T indications, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) for first-line, second-line, or third-line treatment failures or relapse; relapsed follicular lymphoma (FL) after second-line treatment; mantle cell lymphoma (MCL) with multiple treatment failures; unspecified DLBCL; large B-cell lymphoma transformed from FL; primary mediastinal large B-cell lymphoma; and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CART #CancerTreatment #AdvancedMedicineInChina #Lymphoma #FollicularLymphoma #CancerRemission #MedicalTourism #ChinaCare #HealingJourney #CancerFree #Immunotherapy #GlobalHealthcare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Revolutionizing Cancer Treatment: China’s Groundbreaking CAR-T Therapy Targets Glioblastoma
Revolutionizing Cancer Treatment: China’s Groundbreaking CAR-T Therapy Targets Glioblastoma
#CAR_Therapy #Glioblastoma #CancerResearch #InnovativeMedicine
A Chinese medical team has recently made significant progress in t
he field of CAR-T cell therapy, bringing new hope for the treatment of solid tumors such as glioblastoma (GBM). While CAR-T therapy has achieved great success in treating hematologic
al malignancies, its efficacy against solid tumors like glioblastoma remains limited. The innovative research by the Chinese medical team has greatly enhanced the attacking capability of CAR-T cells against solid tumors through the design of high-affinity protein binders from scratch.
The study, published in *Nature Biomedical Engineering* under the title “Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders,” presents a novel Binder CAR strategy that replaces the traditional scFv antibody structure. Through computational design, the Chinese research team precisely constructed a new protein binding domain targeting highly expressed antigens in glioblastoma—EGFR and CD276. This new Binder CAR demonstrated significant anti-tumor effects in experiments compared to traditional scFv CAR, especially in the treatment of glioblastoma, a highly malignant tumor. The Binder CAR not only enhanced tumor-killing capacity but also effectively prolonged the survival time of experimental mice.
This groundbreaking technology showcases China’s strong innovative capability in cancer treatment. The Binder CAR can not only identify tumor antigens more stably and efficiently but also reduces the potential T cell exhaustion issues associated with traditional CAR-T therapy, significantly improving treatment durability. In the future, this strategy is expected to be applied to the treatment of other solid tumors, heralding a new era for CAR-T therapy.
China is not only pioneering the era of CAR-T in solid tumors but has also achieved remarkable success in hematological malignancies. Whether it’s the CD19 CAR-T therapy for relapsed or refractory large B-cell lymphoma (DLBCL) and leukemia that is already on the market, or the BCMA CAR-T therapy for multiple myeloma, China has made substantial progress and is now at the forefront of global CAR-T advancements. Additionally, the number of CAR-T therapies in clinical development is astounding, including dual-target CAR-T therapies targeting CD20, CD22, and CD30, or the recently headline-grabbing universal CAR-T therapies, as well as the explosive news regarding CAR-T therapies for autoimmune diseases. China is in a position of complete leadership. We look forward to bringing more good news to cancer patients worldwide.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CART #CancerTreatment #Glioblastoma #ChinaInnovation #MedicalBreakthrough #SolidTumors #Immunotherapy #CureCancer #Biotech #MedicalResearch
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment
Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment
Lymphoma
#CART #CellDiscovery #Lymphoma #BCellLymphoma #RRLBCL #IL7 #CCL19
In recent years, China has made significant progress in medical innovation, especially in the field of Chimeric Antigen Receptor T-cell (CAR-T) therapy, dramatically changing the landscape of treatment for malignant blood cancers. Recently, a team of medical professors from Zhejiang, China, released the results of a clinical trial demonstrating the breakthrough effectiveness of fourth-generation anti-CD19 CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study, published in the renowned journal *Cell Discovery* (“Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma”), sheds light on this innovative approach.
**New Highlights of CAR-T Therapy**
Traditional anti-CD19 CAR-T cell therapy has already shown excellent efficacy in treating blood cancers like R/R LBCL, but tumor relapse remains a significant challenge. To address this, Chinese researchers have developed a new fourth-generation CAR-T cell therapy that co-expresses two cytokines, IL-7 and CCL19. These cytokines enhance the activity of immune cells, improving CAR-T cells’ anti-tumor effects and extending patient survival.
**Efficacy and Potential**
The Chinese medical team included 39 patients, aged 29 to 73, in this study. They received a single infusion of the fourth-generation anti-CD19 CAR-T cells co-expressing IL-7/CCL19. The results showed that within three months of treatment, the overall response rate (ORR) reached 79.5%, with a complete response rate (CR) of 56.4%. This therapy also demonstrated a notable long-lasting effect, with a median progression-free survival (PFS) of 13 months, and an estimated two-year overall survival rate (OS) of 53.8%.
The study found that the expansion of CAR-T cells in the blood and plasma levels of IL-7/CCL19 were closely associated with clinical outcomes. Higher CAR-T cell expansion and peak concentrations of IL-7/CCL19 were linked to better overall survival (OS), further confirming that this combination can enhance CAR-T cells’ anti-tumor potential.
**Why Is This Study So Important?**
The introduction of this new CAR-T therapy in China marks a significant leap forward in cancer treatment. It not only induces long-lasting remission but also significantly extends patient survival, with manageable safety, offering new hope to patients facing resistant blood cancers. China’s rapid advancements in CAR-T technology showcase its growing influence in the global biotechnology sector.
This groundbreaking research not only solidifies China’s important position in medical innovation but also lays the foundation for future development and application of more CAR-T therapies, potentially bringing revolutionary changes to cancer treatment worldwide.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CAR_Therapy #CancerTreatment #MedicalInnovation #BCellLymphoma #ChinaBiotech #Immunotherapy #FourthGenerationCAR_T #BloodCancer #CytokineTherapy #OncologyBreakthrough #CellDiscovery #CancerResearch #TumorImmunology #PatientSurvival #Hematology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**
**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**
As an innovative immunotherapy, CAR-T therapy has gradually become available in China in recent years, attracting significant attention from patients. Although it is dubbed the “million-dollar therapy” due to its high cost, experts emphasize that CAR-T is not a conventional drug but a “living drug.” Its effectiveness is confirmed, but the outcome largely depends on the skill and experience of the operator. Like a horse-riding competition, the handler must fully understand and control this “good horse.” Early data show promising results, and while the overall treatment cost remains high, its efficacy is undeniable.
To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**
**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**
patient story
In the long journey of life, cancer often strikes like a sudden storm, leaving patients and their families devastated. Mrs. Li, a young and resilient mother from China, was no exception. Two years ago, she was diagnosed with relapsed and refractory B-cell non-Hodgkin lymphoma. The shocking news felt like a bolt from the blue, throwing her once-happy family into the depths of despair.
Traditional chemotherapy and radiation therapy once brought a flicker of hope for Mrs. Li, temporarily alleviating her condition. However, fate seemed to play a cruel trick on her again, as the tumor returned with more aggression, no longer responding to conventional treatments. The repeated rounds of therapy took a toll on her body and spirit. Both Mrs. Li and her family were pushed to the brink of collapse, feeling trapped in a deep abyss with no light of hope in sight.
Just when Mrs. Li was about to give up, fate intervened. Thanks to the relentless efforts of the “Advanced Medicine in China” team, they successfully connected Mrs. Li with the country’s top hematology specialists. After a series of communications and coordination, this expert became her last lifeline, taking on the responsibility of devising the best treatment plan during her darkest hours.
After conducting a comprehensive and detailed examination of Mrs. Li, the expert, relying on extensive experience and professional judgment, decisively recommended CAR-T therapy, a cutting-edge treatment. This innovative immunotherapy acts like a magical key, reactivating the patient’s immune system to precisely target and attack cancer cells, offering a new glimmer of life. Faced with this final hope, Mrs. Li carefully considered her options and bravely decided to seize it, determined to fight once more for her life.
The results were truly remarkable. CAR-T therapy produced astonishing effects in Mrs. Li, like a dazzling light in the darkness. After just a few weeks, follow-up tests showed that her tumor had significantly shrunk, and the symptoms that had once plagued her improved dramatically. This was a pivotal moment, allowing Mrs. Li and her family to rediscover hope for the future.
In the months that followed, under close monitoring and consolidation treatment, Mrs. Li’s condition stabilized, as though the ferocious beast of cancer had been tamed. Ultimately, she achieved a miracle—her cancer reached complete remission. For Mrs. Li and her family, this was nothing short of extraordinary, filling their hearts with overwhelming joy and gratitude. They were not only rekindled with the flame of hope for life but also deeply thankful to the “Advanced Medicine in China” team and CAR-T therapy.
As the recommending team, “Advanced Medicine in China” feels honored to have witnessed Mrs. Li’s recovery journey. This is not just a victory for one patient but a successful step forward in the ongoing battle against cancer, inspiring the team to continue seeking rays of hope for more patients. Mrs. Li’s story has become a powerful tale of triumph, spreading rapidly among fellow patients. Her courage and perseverance have set an example for many others bravely fighting blood cancer, encouraging them to press on and never give up.
Through Mrs. Li’s case, CAR-T therapy in China has once again demonstrated its immense potential in the treatment of lymphoma. Like a rising star, it is bringing new hope to blood cancer patients worldwide, illuminating their path toward overcoming the disease. In the future, CAR-T therapy in China will undoubtedly create more miracles, offering patients the dawn of life and a brighter future.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#patientstory #CARTTherapy #CancerSurvivor #Lymphoma #LymphomaTreatment #BloodCancerAwareness#MedicalMiracles #ChinasMedicalAdvances #CancerResearch #PatientStories #HopeAgainstCancer #Immunotherapy #FightCancer #CancerRemission #CourageToFight #BreakthroughInMedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting
**China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting**
CSCO
#CSCO #CSCO2024 #Lymphoma #CART #LBCL #RRLBCL #ChinaCAR-T
At the 27th Annual Chinese Society of Clinical Oncology (CSCO) Conference, held in Xiamen, China, CAR-T therapy took center stage as a key focus for the treatment of large B-cell lymphoma (LBCL). As a Chimeric Antigen Receptor T-cell (CAR-T) therapy, this innovative approach is revolutionizing the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), offering new hope for patients where traditional therapies have been less effective.
### Breakthroughs in CAR-T Therapy for LBCL
As a major innovation in immunotherapy, CAR-T therapy has shown remarkable efficacy in treating R/R LBCL. Clinical data indicates that about one-third of R/R LBCL patients can achieve long-term remission or even cure through CAR-T therapy. Notably, Axicabtagene ciloleucel (Axi-cel), developed by Fosun Kite Biotechnology, is the first domestically approved CD19-targeted autologous CAR-T product in China. Six-year follow-up results revealed that the two-year overall survival rate was 50.5%, and the six-year lymphoma event-free survival rate was 33.5%.
Meanwhile, Relma-cel, a CAR-T product independently developed by JW Therapeutics in China, has also achieved impressive results. Two-year follow-up data showed a median duration of response of 20.3 months, further highlighting China’s growing research and manufacturing strength in the CAR-T therapy field.
### CAR-T Therapy Expands from Third-Line to Second-Line Use
While CAR-T therapy was initially used only for patients who had failed multiple lines of treatment, it is now being increasingly applied in second-line settings. Recent studies have shown that CAR-T therapy outperforms traditional high-dose chemotherapy and autologous stem cell transplant (ASCT) in certain patient groups. For example, the ZUMA-7 study demonstrated that Axi-cel significantly improved event-free survival (EFS) for LBCL patients treated in the second-line setting, with a median EFS of 8.3 months, compared to 2 months in the ASCT group.
As more research progresses, CAR-T therapy has been recommended by leading clinical guidelines, such as the National Comprehensive Cancer Network (NCCN), for use in patients with primary refractory or early relapsing LBCL. This shift underscores CAR-T’s growing role in earlier stages of treatment, providing more therapeutic options for patients.
### Challenges and Future Prospects
In the exploration of CAR-T as a first-line treatment, promising results are beginning to emerge. The ZUMA-12 study evaluated the use of Axi-cel in high-risk LBCL patients in the first-line setting, with a three-year follow-up showing an overall survival rate of 90.6%. These findings suggest that CAR-T therapy could become an important treatment option for high-risk patients even in the first-line setting.
### China’s Leading Role in CAR-T Therapy
China is rapidly emerging as a global leader in the development and commercialization of CAR-T therapy. With domestically developed products like Axi-cel and Relma-cel achieving significant progress both in China and globally, China’s competitive edge in this field is becoming increasingly evident. As the technology matures and more clinical data are released, the future of CAR-T therapy in LBCL treatment looks exceptionally bright.
The 2024 CSCO Annual Meeting showcased China’s strong commitment to advancing CAR-T therapy. As breakthroughs and challenges coexist, CAR-T therapy is poised to continue playing a critical role in the treatment of large B-cell lymphoma, with China leading the way in this global medical revolution.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#LymphomaTreatment #ImmunotherapyRevolution #CancerResearch #MedicalInnovation #BCellLymphoma
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL
**Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL**
T-ALL
#CAR-TTherapy #TALL #ALL #Leukemia #RelapsedLeukemia #TCellLeukemia #CD5 #CD7 #CART
Recently, a collaborative research study conducted by multiple Chinese medical and research institutions was published in *Nature Medicine*. This study, titled “Allogeneic CD5-specific CAR-T Therapy for Relapsed/Refractory T-ALL: A Phase 1 Trial,” demonstrated the potential of CD5 CAR-T cells in treating relapsed/refractory acute T-cell lymphoblastic leukemia (R/R T-ALL).
### Innovative Therapy Brings Hope
For a long time, patients with relapsed/refractory T-ALL have lacked effective treatment options and faced a poor prognosis. In recent years, CD7 CAR-T cell therapy has shown some efficacy in these patients, but CD7-negative relapse remains a significant challenge. This study focuses on evaluating the safety, efficacy, and pharmacokinetics of CD5 CAR-T cells, offering new insights for future treatments.
The study included 19 patients, most of whom had previously received CD7 CAR-T therapy. Results showed that this therapy was safe, with no dose-limiting toxicity observed, and adverse events were primarily manageable hematologic toxicity. In terms of efficacy, all patients achieved complete remission within 30 days of treatment. The study also demonstrated, for the first time, the persistence of CD5 CAR-T cells in the body and their ability to eliminate CD5+ T cells, indicating strong anti-tumor activity.
### Breakthrough in Treating Relapsed Patients
In addition to safety and efficacy, the research team explored the coexistence of CD7 CAR-T and CD5 CAR-T cells and studied immune cell changes in the patients. For those who relapsed after CD7 CAR-T treatment with CD7-negative cells, CD5 CAR-T offered a new salvage therapy, providing additional treatment options for such patients.
### Multidisciplinary Collaboration Drives Clinical Progress
Unlike CAR-T therapies for B-cell tumors, treating T-cell malignancies poses more challenges, particularly in controlling immune deficiencies. Dr. Jing Pan and her team conducted in-depth research on target selection and relapse mechanisms, while also focusing on balancing treatment safety and efficacy.
This study was made possible by the collaborative efforts of various medical institutions in China, collectively opening up a new therapeutic pathway for T-cell tumor patients.
### Looking Ahead
As innovations and advances in T-ALL treatment continue, the team plans to further research CD5 CAR-T therapy and collaborate with experts across various fields to optimize CAR-T treatment protocols, helping more patients with T-cell lymphoblastic tumors overcome their diseases.
This series of research achievements not only brings new hope to patients with R/R T-ALL but also provides valuable insights for the future development and optimization of CAR-T therapies. The team remains committed to a patient-centered approach, striving to drive continuous breakthroughs and innovations in T-cell tumor treatment.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#Immunotherapy #CancerTreatment #TALLResearch #LeukemiaBreakthrough #Hematology #CellTherapy #CancerInnovation #CancerResearch #ClinicalTrials #MedicalBreakthrough
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients
### China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients
CAR-T Therapy
Multiple myeloma remains a difficult-to-cure disease, and every year, countless patients around the world face this devastating diagnosis. While treatment options have improved in recent years, and patients’ survival times have extended, drug resistance remains a significant challenge. For patients who have experienced multiple relapses and are resistant to various treatments, the future can seem bleak. Fortunately, with the emergence of **BCMA CAR-T cell therapy**, a new ray of hope is illuminating the path for these patients.
This is the story we’re sharing today, about a 76-year-old female patient who regained control of her life through CAR-T therapy.
#### The First Encounter with the Disease
In 2020, this Chinese 76-year-old woman noticed a decline in appetite and a rapid weight loss, accompanied by persistent rib pain. She had no idea that these symptoms were early signs of multiple myeloma. After several medical tests, her Chinese doctors confirmed the diagnosis: 31% of her bone marrow cells were plasma cells, her M-protein levels reached 85.7 g/L, and calcium levels in her blood were abnormally high. Multiple bones throughout her body also showed signs of significant damage.
The diagnosis left the patient shocked and confused. Multiple myeloma wasn’t her first health challenge; she also had a history of Parkinson’s disease. However, she remained hopeful, believing that with the right treatment, her condition could be controlled. But fate had other plans.
#### The Struggle and Relapse
At the beginning of 2023, the patient’s condition relapsed rapidly. Due to a prolonged lack of regular treatment, her disease worsened, and she became resistant to many standard therapies. After extensive tests, her medical team discovered that she had a high-risk mSMART 3.0 profile, with genetic abnormalities including 1q21 amplification and a t(4;14) translocation, making her prognosis extremely poor. She was now considered a “triple-refractory” patient, resistant to three main treatment categories.
Faced with this complex and challenging situation, the Chinese doctors didn’t give up. After multiple discussions and research, they recommended a cutting-edge therapy — **BCMA CAR-T cell therapy**. This treatment involves modifying the patient’s immune cells to target and destroy cancer cells. However, to undergo this advanced therapy, the patient first needed to undergo **bridging treatment** to reduce the tumor burden in her body.
#### Bridging Treatment: A Turning Point
To prepare for CAR-T therapy, the Chinese doctors initially prescribed the **DKD regimen**, a combination therapy intended to quickly reduce the cancer cell load. However, the first treatment cycle didn’t bring significant improvement, and her free light chain levels remained high. Both the patient and her family felt disappointed, but the Chinese doctors acted quickly, switching to the **KAD regimen**, which included **liposomal doxorubicin** to further enhance the treatment’s effectiveness.
This adjustment brought immediate results. After a few weeks, her free light chain levels began to drop, and her condition showed partial remission (PR). This meant she was finally ready for CAR-T cell therapy.
#### The Miracle of CAR-T Therapy
CAR-T therapy is a breakthrough technology where the patient’s immune cells are extracted, genetically modified to recognize and destroy cancer cells, and then reintroduced into the body. These engineered cells act like precision-guided weapons, specifically targeting her cancer cells.
The patient responded positively to the treatment. Within just a few weeks, her condition was significantly controlled, with results showing a very good partial response (VGPR). For such a complex case of relapsed and refractory disease, this was a major success.